Coronavirus Pandemic: Emergence, Transmission, Preventive Measures and Management
Coronavirus is found in animals and, rarely, can be transmitted from animals to humans and then spread person to person. An occurrence of the coronavirus infection (COVID-19) in China is causing global concern. It came from a seafood and meat market in Wuhan, China, in December 2019. It has since spread to many countries around the world including India. World Health Organization (WHO) declared novel coronavirus eruption a “pandemic” on March 11th, 2020. Patients infected with the COVID-19 virus will experience mild to moderate respiratory illness. Older people and those with underlying medical problems like cardiovascular disease, diabetes, chronic respiratory disease, and cancer are more likely to develop serious illness. Prevent spread of infection by washing hands or using an alcohol based rub frequently and not touching face. This virus transmits primarily through droplets of saliva or discharge from the nose when adiseased person coughs or sneezes, so it’s important to cover face by mask and coughing into a flexed elbow at public places. Currently there are no specific vaccines or treatments for COVID-19. In this review, we summarize recent information about the emergence, tansmission, preventive measures and therapeutic options available now.
2. Tan WJ, Zhao X, Ma XJ, et al. A novel coronavirus genome identified in a cluster of pneumonia cases — Wuhan, China 2019–2020. China CDC Weekly 2020; 2: 61-2.
3. Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. A novel coronavirus emerging in China — key questions for impact assessment. N Engl J Med 2020; 382:692-4.
4. Zhang W, Du R-H, Li B, Zheng X-S, Yang X-L, Hu B, Wang Y-Y, Xiao G-F, Yan B, Shi Z-L, Zhou P. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect 2020; 9: 386-389.
5. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, Zou X, Yuan S, Shang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single- centered, retrospective, observational study. Lancet Respir Med 2020 Feb 24. pii: S2213-2600(20)30079- DOI: 10.1016/S2213-2600(20)30079-5.
6. Peiris J, Guan Y, Yuen K. Severe acute respiratory syndrome. Nat Med 2004;10 (12):S88–97.
7. Pyrc K, Berkhout B, Van Der Hoek L. Identification of new human coronaviruses. Expert Review of Anti-infective Therapy 2007; 5 (2):245–53.
8. Rahman A, Sarkar A. Risk factors for fatal middle east respiratory syndrome coronavirus infections in Saudi Arabia: analysis of the WHO Line List, 2013– 2018. Am J Public Health 2019; 109(9):1288–93.
9. Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019; 17(3):181–92.
10. Organization WH. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases: interim guidance, 2 March 2020. World Health Organization, 2020.
11. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. The Lancet 2020.
12. Riou J, Althaus CL. Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. Eurosurveillance. 2020;25(4).
13. Parry J. China coronavirus: cases surge as official admits human to human transmission. British Medical Journal Publishing Group; 2020.
14. Li W, Shi Z, Yu M, Ren W, Smith C, Epstein JH, et al. Bats are natural reservoirs of SARS-like coronaviruses. Science. 2005; 310(5748):676–9.
15. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020.
16. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020
17. Li Q, Guan X,WuP, et al. Early transmission dynamics inWuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020; NEJMoa2001316.
18. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020.
19. Kang CK, Song KH, Choe PG, Park WB, Bang JH, Kim ES, et al. Clinical and epidemiologic characteristics of spreaders of middle east respiratory syndrome coronavirus during the 2015 outbreak in Korea. J Korean Med Sci. 2017; 32(5):744–9.
20. Guo Y, Korteweg C, McNutt MA, Gu J. Pathogenetic mechanisms of severe acute respiratory syndrome. Virus Res 2008; 133:4‑12.
21. Gu J, Korteweg C. Pathology and pathogenesis of severe acute respiratory syndrome. Am J Pathol 2007; 170: 1136‑47.
22. Laboratory guidance Available at https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical Accessed February 3, 2020
23. Infection Control: Novel Coronavirus 2019 (2019-nCoV) | CDC [Internet]. 2020 [Published February 2, 2020]. Available at https:// www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control.html
24. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. 2020. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus 434 (2019-nCoV) in vitro. Cell Res 2019–2021.
25. Lin SY, Liu CL, Chang YM, Zhao J, Perlman S, Hou MH. Structural basis for the identification of the N‑terminal domain of coronavirus nucleocapsid protein as an antiviral target. J Med Chem 2014;57: 2247‑57.
26. Interim Clinical Guidance for Management of Patients with Confirmed 2019 Novel Coronavirus (2019-nCoV) Infection [Internet]. 2020 Accessed February 4, 2020.
27. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected [Internet]. [cited February 9, 2020].
28. Three Drugs Fairly Effective on Novel Coronavirus at Cellular Level‑Xinhua. Available from: http://www.xinhuanet.com/ English /2020‑01/30/c_138742163.htm. [Last accessed on 2020 Feb 03].
29. Coronavirus Outbreak: Cocktail of Flu, HIV Drugs Appears to Help Fight Virus, Say Thai Doctors. India Today; 03 February, 2020.
30. Aguiar ACC, Murce E, Cortopassi WA, Pimentel AS, Almeida M, Barros DCS, et al. Chloroquine analogs as antimalarial candidates with potent in vitro and in vivo activity. Int J Parasitol Drugs Drug Resist. 2018; 8 (3):459–64.
31. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis. 2003; 3(11):722–7.
32. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69.
33. Golden EB, Cho HY, Hofman FM, Louie SG, Schonthal AH, Chen TC. Quinoline-based antimalarial drugs: a novel class of autophagy inhibitors. Neurosurg Focus. 2015; 38(3):E12.
34. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020. https://doi.org/10.1038/s41422-020- 0282-0.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).